OncoNano Medicine, Inc. is a biotechnology and health care startup founded in 2014 in the United States. The company is focused on developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. By leveraging the proven, simple, and effective identifier of diseased tissue, namely pH variability, OncoNano Medicine aims to create a broad range of highly targeted therapeutics and imaging agents. Their lead program, ONM-100, is designed to target tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.
Their recent Series B investment of $18.40M on 25 October 2021 came from the Cancer Prevention and Research Institute of Texas. This investment reflects the growing interest and support for OncoNano Medicine's innovative approach to addressing cancer diagnosis and treatment. The company's novel focus on targeting tumor acidosis and utilizing pH variability as a diagnostic tool presents a promising opportunity in the field of oncology and medical imaging.
OncoNano Medicine's strategic emphasis on leveraging pH variations for disease detection and treatment, combined with the recent substantial funding, positions the company favorably for advancing their research, development, and commercialization efforts. As the company continues to progress, it will be essential to monitor how they utilize the recent investment to further their mission of revolutionizing cancer identification and treatment through pH-activated compounds.
